Please assess the completion status of the following clinical trial:

Trial Title: Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe stable Chronic Obstructive Pulmonary Disease (COPD) stage II or stage III according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines (2009)~* Qualifying spirometry, Forced Expiratory Volume in one second (FEV1) and post-bronchodilator FEV1/FVC (Forced Vital capacity)~* Smoking history ≥ 10 pack years~Exclusion Criteria:~* Pregnant women or nursing mothers or women of child-bearing potential not using adequate contraception~* Cardiac abnormality~* History of asthma~* Contraindications to cardiopulmonary exercise testing~* Participation in active phase of pulmonary rehabilitation program~* History of cancer within the past 5 years~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- indacaterol and glycopyrronium bromide (QVA149) (Type: EXPERIMENTAL): QVA149 delivered once daily via single-dose dry powder inhaler.
- placebo (Type: PLACEBO_COMPARATOR): Placebo, delivered once daily via single-dose dry powder inhaler.
- tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium delivered once daily via HandiHaler® device.

Based on this trial design, predict the completion outcome and termination type (if applicable).